BioCentury
ARTICLE | Company News

Anika, Sanofi neurology news

March 17, 2014 7:00 AM UTC

On March 10, the U.S. District Court for the District of Massachusetts granted a joint motion filed by Anika and Sanofi's Genzyme Corp. unit to lift a stay and dismiss a patent infringement lawsuit concerning Anika's Monovisc. The court issued an order dismissing the litigation with prejudice, resolving the companies' dispute. Monovisc - a single injection product that delivers hyaluronic acid from a non-animal source - was approved by FDA in February to treat pain and improve joint mobility in patients with osteoarthritis (OA) of the knee. The DePuy Mitek Inc. subsidiary of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) has exclusive rights from Anika to develop and commercialize Monovisc in the U.S. Anika said the resolution of the Genzyme litigation triggered a $17.5 million milestone payment to Anika from J&J (see BioCentury, March 3). ...